Iron Status, Erythropoietin, and Cancer Incidence in the General Population
Siem J van Alfen, Pien Rawee, Li Luo, Ilja M Nolte, Bert van der Vegt, Jenny E Kootstra‐Ros, Stephan J L Bakker, Ron T Gansevoort, Thera P Links, Wouter T Zandee, Michele F Eisenga · 2026
Read Iron Status, Erythropoietin, and Cancer Incidence in the General Population by Siem J van Alfen, Pien Rawee, Li Luo, Ilja M Nolte, Bert van der Vegt, Jenny E Kootstra‐Ros, Stephan J L Bakker, Ron T Gansevoort, Thera P Links, Wouter T Zandee, Michele F Eisenga (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13154720.txt.
Description
Siem van Alfen and co-authors probe in a 2026 study whether iron state and a blood hormone predict cancer in the general public. Iron feeds cell growth, and imbalance has been tied to cancer, though proof is mixed. The hormone erythropoietin may also sway tumor growth over time.
Data cover 6,109 adults in a Dutch cohort, mean age 52, followed a median 18.5 years. Over that span, 1,090 people developed cancer of some type. Higher hormone levels linked to 26% greater overall cancer risk in adjusted models. Higher hepcidin, a liver signal that locks iron away, linked to lower risk instead. Dropping early diagnoses left both of those links standing in the checks.
Catalog record
| CREATOR | Siem J van Alfen, Pien Rawee, Li Luo, Ilja M Nolte, Bert van der Vegt, Jenny E Kootstra‐Ros, Stephan J L Bakker, Ron T Gansevoort, Thera P Links, Wouter T Zandee, Michele F Eisenga |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |